Advanced searches left 3/3

Carcinoma pembrolizumab - BioProject

Summarized by Plex Scholar
Last Updated: 03 November 2021

* If you want to update the article please login/register

Molecular predictors of response to pembrolizumab in thymic carcinoma

Thymic carcinoma is rare and has a poorer diagnosis than thymomas. We formerly performed a solitary center stage II research of pembrolizumab in patients with innovative thymic carcinoma, revealing a 22. 5% response rate. We discovered that expression of PDL1 and alterations in genetics or paths that correlated with PD-L1 expression might be potential forecasters for response or resistance to immunotherapy in patients with advanced thymic carcinoma.

Source link: https://www.ncbi.nlm.nih.gov/bioproject/753518

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions